With advances in supportive care, autologous hematopoietic cell transplant (AHCT) is increasingly being performed for patients older than 60 years. We analyzed patients receiving an AHCT for multiple myeloma or lymphoma in a contemporary cohort (2010)(2011)(2012), with consistent treatment and supportive care and compared outcomes [CTCAE grade 3-5 toxicities, nonrelapse mortality (NRM) and overall-survival (OS)] of younger (40-59 years, n 5 77) versus older (60 years, n 5 67) recipients. The proportion of patients with neutropenic infections was higher in the older group (64% vs. 44%; P 5 0.02). The proportion of patients with any grade 3-5 toxicity was also higher in the older group (84% vs. 67%, P 5 0.03). In multivariate analysis, older age was significantly associated with higher odds (OR: 2.57, 95% CI:1.09-6.05) of grade 3-5 toxicity. The NRM was 3% (older) vs. 0% (younger) at 1 year. The probability of OS at 2 years was lower in the older group (76% vs. 90%, P 5 0.04). Though AHCT can be performed safely in older recipients, the higher toxicity and slightly higher NRM in this population needs attention. Studies focusing on riskstratification in older patients would further help predict toxicity. Further studies addressing enhanced supportive care needs for older patients who are most likely to benefit are indicated.
| I N T R O D U C T I O N
High dose chemotherapy and autologous hematopoietic stem cell transplant (AHCT) is an effective treatment strategy for many patients with lymphoma and multiple myeloma. [1] [2] [3] [4] However, the procedure continues to be associated with complications, commonly including mucositis, infections, hematologic, and other organ toxicities. [5] [6] [7] [8] The risk of morbidity and mortality is higher in older AHCT recipients as compared to younger AHCT recipients in some studies, 3, 5, 9 whereas other studies demonstrate similar outcomes in older versus younger patients. [6] [7] [8] Recent advances in HCT strategies with improved supportive care have resulted in reduction in nonrelapse mortality (NRM) and increased use of HCT in older recipients (>60 years of age). 10, 11 Despite these advancements, the true burden of morbidity suffered by the elderly population after AHCT is still unknown. Therefore, we explored if age played a role in predicting transplantation related toxicity and mortality following AHCT. We analyzed patients receiving an AHCT for multiple myeloma or lymphoma in a contemporary cohort AHCT recipients.
| P A T I E NT S A ND M E T HOD S
Patients 40 years of age who underwent an AHCT at the University of Minnesota between 2010 and 2012 for lymphoma (Hodgkin's or Non-Hodgkin's) or multiple myeloma were included in the study (n 5 144). Approval for retrospective chart reviews was obtained from abstracted through retrospective chart reviews. Toxicities were graded using the CTCAE version 4.0 of the National Cancer
Institute. Adverse events were graded as 0 indicating none, 1 5 mild, 2 5 moderate, 3 5 severe, 4 5 life threatening or debilitating, and 5 5 death.
| Statistical analysis
The study is a retrospective cohort study. 
| R E S U L T S
The study included 144 patients 40 years old. Demographics and HCT characteristics are described in Table 1 in the older group versus 22% in the younger group had a HCT-CI comorbidity score of 3 (P 5 0.72).
| Toxicities post HCT
We examined 17 categories of nonhematologic grade 3-5 toxicities in both patient groups (Figure 1) . The proportion of patients with any 
| Risk factors for development of grade 3-5 toxicity
A multivariable regression model was used to determine the odds of having at least one grade 3-5 toxicity ( 
| Other outcomes
We also compared time to neutrophil and platelet recovery, overall survival, and NRM within the first year post AHCT. There was no difference in time to neutrophil (median 11 days and 10 days in old and young groups, respectively) and platelet engraftment (median 18 days and 19 days in the old and young groups, respectively) between the two age groups. Two older recipients (cumulative incidence of NRM:
3%, 95% CI: 1%-7%) and no younger recipients had NRM within 1 year, P 5 0.05. After a median follow-up of 2 years, the probability of overall survival at 2 years was lower in the older group (76%, 95% CI: 65%-87%) vs. younger group (90%, 95%CI: 82%-98%), P 5 0.04.
Overall 20 patients died within first 2 years of HCT, 14 in the older group and 6 in the younger group. All six patients in the younger group An odds ratio > 1 represents a greater risk of toxicity.
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| DISCUSSION
There is conflicting data regarding toxicity and mortality in older AHCT recipients versus younger AHCT recipients. 3, [5] [6] [7] 9 The purpose of this study was to explore if age played a role in predicting transplantation related toxicity and mortality following AHCT for lymphoma and multiple myeloma.
In our analysis, after adjustment for gender and disease, older age was significantly associated with higher odds of developing grade 3-5 toxicities. These findings are consistent with other studies that reported increased frequency of specific toxicities such as cardiac toxicities, arrhythmias and oral or gastrointestinal toxicities among older patients with multiple myeloma undergoing hematopoietic cell transplant. 5, 15, 16 More frequent mucositis, cardiovascular events and neurologic complications have also been reported in older patients with lymphoma undergoing AHCT. 5, [17] [18] [19] Higher toxicity in older patients might be explained by the fact that increased age is associated with increased co-morbid conditions and physiological changes resulting in diminished cardio-respiratory reserve. 20, 21 In our study, we did not find higher cardiac or oral or GI toxicities in the older versus younger groups. This difference may be because our selected older HCT cohort had similar comorbidities (as screened by HCT-CI) and KPS as our younger cohort. We found that the older group had a higher frequency of neutropenic infections as compared to the younger group, suggesting perhaps immunosenescence in the elderly HCT recipients. higher toxicities in women. [23] [24] [25] The etiology behind these differences are unclear although differences in levels of metabolic enzymes and drug pharmacokinetics have been postulated. 26 Patients with NHL at our institution were more likely to undergo chemotherapy using a TBI based regimen (cyclophosphamide and TBI) as compared to other diseases (93% of patients with NHL versus 0% in Hodgkin's lymphoma or 0% with multiple myeloma). Higher rates of death due to toxicity have been described in older patients with lymphoma undergoing a TBIbased preparative regimen. 27 Another report from Center for international Blood and Marrow Transplant Research (CIBMTR) compared different conditioning regimens in patients undergoing autologous HCT for lymphoma and reported higher risk of idiopathic pneumonia syndrome (IPS) with TBI-based regimens in patients with non Hodgkin's lymphoma, and higher mortality in patients with Hodgkin's lymphoma undergoing an AHCT with TBI-based conditioning. 3 We did not find a difference in toxicity by TBI-based versus non-TBI based conditioning in older recipients, however, in younger patients, a slightly higher proportion (82%) of patients experienced grade 3-5 toxicities amongst those who received TBI-based conditioning as compared to those without TBI-based conditioning (59%).
To conclude AHCT can be performed safely in older recipients.
However, the higher toxicity and slightly higher NRM in this population needs attention. Studies focusing on risk-stratification in older patients (including geriatric assessments) would further help predict toxicity.
Further studies addressing enhanced supportive care needs for older patients who are most likely to benefit are indicated.
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